Recovery from Heart Failure: Microvascular Mechanisms

However, the cellular programs underlying this recovery remain unclear.

Methods

Myocardial tissues were obtained from patients with HF at the time of LVAD implantation (pre-LVAD) and explantation (post-LVAD) for histological analysis and single-nucleus RNA sequencing (snRNA-seq). A murine model of HF recovery, combined with lineage tracing studies, was employed to define cellular sources of vascular repair. Cardiac function, fibrosis, and vascular density were assessed using echocardiography, histology, and fluorescent microsphere perfusion.

A patient-derived cardiac non-myocyte culture system was established to interrogate mechanisms of cell-fate regulation. Results: Post-LVAD myocardial tissues exhibited reduced fibrosis and increased capillary density compared to pre-LVAD samples. Across samples, fibroblast abundance inversely correlated with endothelial cell abundance, consistent with enhanced angiogenesis during recovery.

SnRNA-seq identified a fibroblast subset predisposed to undergo mesenchymal-to-endothelial transition, acquiring an endothelial cell identity. Additionally, non-myocytes from pre-LVAD hearts proliferated poorly and failed to form vascular structures, whereas non-myocytes from post-LVAD hearts displayed greater proliferative and angiogenic capacity, forming vessel-like structures, reinforcing the association of HF recovery with angiogenic reprogramming.

Mechanistically, knockdown of c-Myc by siRNA shifted post-LVAD non-myocytes to a pre-LVAD-like state, while c-Myc overexpression by mRNA in pre-LVAD cells induced a post-LVAD-like phenotype, implicating c-Myc as one contributor to this fate switch. A model of heart failure recovery in mice mimicked the histological and functional changes in patients, with physiological evidence of increased microvascular perfusion, associated with a fibroblast-to-endothelial transition documented by lineage tracing.

Conclusions: HF recovery involves reduced fibrosis and enhanced microvascularization, partly driven by fibroblast-to-endothelial cell fate transition. c-Myc functions as one regulator of this transition, offering a mechanistic entry point to develop regenerative therapies in HF.